Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/26/2025

Alternatives to Methocarbamol for Muscle Relaxation

First-Line Alternative: Cyclobenzaprine

  • The American Geriatrics Society recommends cyclobenzaprine 5 mg three times daily as the preferred alternative to methocarbamol for acute musculoskeletal pain, due to its consistent evidence of efficacy and favorable side effect profile at this lower dose 1
  • Treatment with cyclobenzaprine should be limited to 2-3 weeks maximum, as recommended by the American Geriatrics Society 1

Important Caveats for Cyclobenzaprine

  • Cyclobenzaprine, structurally related to amitriptyline, carries anticholinergic effects such as dry mouth, constipation, urinary retention, and confusion, as noted by the Mayo Clinic Proceedings 2
  • The Mayo Clinic Proceedings also warns that cyclobenzaprine is contraindicated with MAO inhibitors due to serotonin syndrome risk 2
  • Elderly patients should avoid cyclobenzaprine due to increased fall risk and anticholinergic burden, as recommended by the Journal of the American Geriatrics Society 4

Second-Line Alternatives

Baclofen (GABA-B Agonist)

  • Baclofen is appropriate for true muscle spasm from central nervous system pathology, with fair evidence for spasticity and minimal data for peripheral musculoskeletal pain, as noted by the Journal of the American Geriatrics Society 1
  • The Journal of the American Geriatrics Society recommends starting baclofen at 10 mg/day, increasing weekly by 10 mg up to 30 mg/day 6
  • Baclofen requires slow tapering to avoid delirium and seizures, as warned by the Journal of the American Geriatrics Society 5

Tizanidine (Alpha-2 Agonist)

  • Tizanidine has fair evidence for spasticity conditions and some data for musculoskeletal pain, but is not as extensively studied as cyclobenzaprine for acute musculoskeletal conditions, as noted by the Journal of the American Geriatrics Society 1

Carisoprodol

  • The Mayo Clinic Proceedings recommends avoiding carisoprodol entirely due to its high abuse potential, removal from European markets, and requirement for slow tapering to prevent severe withdrawal symptoms 2

Other Muscle Relaxants with Limited Evidence

  • Metaxalone is contraindicated in hepatic/renal dysfunction and associated with hemolytic anemia, as noted by the Mayo Clinic Proceedings 2
  • Orphenadrine has significant anticholinergic burden and cardiovascular instability risk, as warned by the Mayo Clinic Proceedings 2

Non-Pharmacologic and Adjunctive Options

For Musculoskeletal Pain

  • The American Heart Association recommends acetaminophen as first-line for inflammatory/musculoskeletal pain, with caution for doses ≥4g daily that may increase blood pressure, as noted in Circulation 8
  • Topical agents such as lidocaine, diclofenac, and capsaicin can be used for localized pain, as recommended in Circulation 8

For Neuropathic Components

  • If pain has neuropathic features, consider SSRIs rather than muscle relaxants, as they target multiple symptoms with better tolerability in most patients, as noted in Circulation 8

Special Population Considerations

Older Adults

  • In elderly patients, methocarbamol or metaxalone may be safer choices than cyclobenzaprine if a muscle relaxant is necessary, due to lower anticholinergic burden, as recommended by the Journal of the American Geriatrics Society and Circulation [4] [8]
  • All muscle relaxants increase fall risk and should be used cautiously in elderly patients, as warned by the Journal of the American Geriatrics Society [4] [5]

Patients with Cardiovascular Disease

  • Methocarbamol and metaxalone are preferred over cyclobenzaprine due to fewer cardiovascular and anticholinergic effects, as recommended by Circulation 8

Perioperative Setting

  • All muscle relaxants, including alternatives, should be held on the day of surgery due to sedation and cardiovascular effects, as recommended by the Mayo Clinic Proceedings [2] [3] 7